{
    "clinical_study": {
        "@rank": "1459", 
        "acronym": "OX40 Breast", 
        "arm_group": [
            {
                "arm_group_label": "15 Gy", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive a radiation dose of 15 Gy to their liver or lung metastases.  Patients receive a dose of anti-OX40 antibody following radiation and on Days 3, and 5."
            }, 
            {
                "arm_group_label": "20 Gy", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of anti-OX40 antibody following radiation and on Days 3, and 5."
            }, 
            {
                "arm_group_label": "25 Gy", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of anti-OX40 antibody following radiation and on Days 3, and 5."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test the investigational antibody, anti-OX40, in combination with\n      stereotactic body radiation in breast cancer patients that have liver or lung metastases and\n      have received systemic therapy and have progressive disease.  The investigators hypothesize\n      that SBRT directed at metastatic breast cancer lesions will result in a systemic anti-tumor\n      immune system response. This amplified and directed immune response could result in\n      anti-tumor responses."
        }, 
        "brief_title": "Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions", 
        "completion_date": {
            "#text": "February 2023", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Breast Cancer", 
            "Lung Metastases", 
            "Liver Metastases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary", 
                "Lung Neoplasms", 
                "Liver Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed breast cancer with clinical evidence of stage 4 disease\n\n          -  Measurable disease and at least one lesion in either liver or lung that is amenable\n             to stereotactic body radiation\n\n          -  One site of disease that will not receive radiation\n\n          -  Patients with hormone receptor positive breast cancer must have received prior\n             anti-hormonal therapy for metastatic disease and have progressed and patients with\n             hormone receptor negative breast cancer must have received at least one prior\n             chemotherapy regimen and progressed.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n\n          -  Women of childbearing potential must have a negative pregnancy test on the day\n             treatment starts and must avoid becoming pregnant while on treatment. Men must avoid\n             fathering a child while on treatment.\n\n          -  Patients must have blood test results within pre-specified range\n\n          -  No active bleeding\n\n          -  No clinical coagulopathy (INR <1.5, PT <16 seconds, PTT < 38 seconds) within 28 days\n\n          -  Anticipated lifespan greater than 12 weeks\n\n        Exclusion Criteria:\n\n          -  Active infection requiring systemic antibiotics.\n\n          -  Active autoimmune disease as defined by the autoimmune disease assessment tool.\n\n          -  Previous treatment with mouse monoclonal antibodies\n\n          -  At least 28 days since prior chemotherapy or monoclonal antibody therapy (trastuzumab\n             or bevacizumab). Patients who have been on hormonal therapy can continue on therapy\n             at the discretion of the investigator. Bisphosphonate therapy is acceptable during\n             study participation.\n\n          -  Diagnosis of a solid tumor malignancy (excluding non-melanoma skin cancer) within 3\n             years of enrollment.\n\n          -  Need for chronic maintenance oral steroids.\n\n          -  Active brain metastatic disease.  Treated brain metastases with surgery, gamma-knife\n             radiosurgery or radiation and stable for at least 4 weeks and off steroids are\n             eligible.\n\n          -  No metastatic site amenable to SBRT\n\n          -  Pregnant or lactating women, as treatment involves risks to the embryo or fetus.\n\n          -  Other medical or psychiatric conditions that in the opinion of the Principal\n             Investigator would preclude safe participation in protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01642290", 
            "nct_id": "NCT01862900", 
            "org_study_id": "12-017A"
        }, 
        "intervention": {
            "arm_group_label": [
                "15 Gy", 
                "20 Gy", 
                "25 Gy"
            ], 
            "description": "Patients receive 3 doses of anti-OX40; one on Days 1, 3, and 5", 
            "intervention_name": "anti-OX40 antibody", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast Cancer", 
            "Metastatic", 
            "Lung metastases", 
            "Liver metastases", 
            "Stereotactic body radiation", 
            "anti-OX40 antibody"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "link": {
            "description": "Providence Cancer Center", 
            "url": "http://oregon.providence.org/patients/programs/providence-cancer-center-clinical-trials/Pages/default.aspx"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97213"
                }, 
                "name": "Portland Providence Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Marka R Crittenden, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Brendan Curti, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Steven Seung, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Steven Bader, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christine Cha, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd Crocenz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rachel Sanborn, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Solhjem, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Walter J. Urba, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alice Wang-Chesebro, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katie Strauss, RN", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Smith, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alison Conlin, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.", 
        "other_outcome": {
            "description": "Patients will provide 9 blood samples over 36 days to measure the number of CD4+ and CD8+ T Cells.", 
            "measure": "Determine the influence of anti-OX40 and radiation on circulating CD4+ and CD8+ T cells.", 
            "safety_issue": "No", 
            "time_frame": "Screening to Day 36"
        }, 
        "overall_contact": {
            "email": "nicole.moxon@providence.org", 
            "last_name": "Nikki Moxon, RN", 
            "phone": "(503) 215-2619"
        }, 
        "overall_contact_backup": {
            "email": "brenda.fisher@providence.org", 
            "last_name": "Brenda Fisher, RN", 
            "phone": "(503) 215-2613"
        }, 
        "overall_official": [
            {
                "affiliation": "Providence Cancer Center, Earle A. Chiles Research Institute", 
                "last_name": "Marka R Crittenden, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Providence Cancer Center, Earle A. Chiles Research Institute", 
                "last_name": "Brendan Curti, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Providence Cancer Center, Earle A. Chiles Research Institute", 
                "last_name": "Steven Seung, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Providence Cancer Center, Earle A. Chiles Research Institute", 
                "last_name": "Alison Conlin, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A dose limiting toxicity (DLT) is defined as any greater than or equal to grade 3 non-hematologic toxicity (except hypothyroidism or vitiligo) that in the opinion of the investigator is considered at least possibly related to treatment.  Grade 3 or 4 hematologic toxicities that take longer than 10 days to resolve will be considered DLTs. Patients will have 8 clinic visits over 36 days to identify toxicities.", 
            "measure": "Determine the maximum tolerated dose and safety profile of radiation administered in combination with anti-OX40 in patients with metastatic breast cancer.", 
            "safety_issue": "Yes", 
            "time_frame": "From Day 1 to Day 36"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862900"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patients will have CT scans for tumor measurements at Day 36.  Patients achieving a radiographic response, or are stable, will be followed monthly with physical exam and laboratory studies with CT (or other imaging as deemed appropriate) scans obtained every 3 months (\u00b1 2 weeks) for up to 24 months and then ever 6 months (\u00b1 2 weeks) for up to 4 years.", 
            "measure": "Estimate the response rate of combined modality treatment in both irradiated and non-irradiated tumors.", 
            "safety_issue": "No", 
            "time_frame": "Day 36"
        }, 
        "source": "Providence Health & Services", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Robert W. Franz Cancer Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Providence Cancer Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Providence Cancer Center, Earle A. Chiles Research Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Providence Health & Services", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}